Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 23 | 2024 | 1144 | 2.020 |
Why?
|
| Cerebral Hemorrhage | 11 | 2017 | 183 | 1.650 |
Why?
|
| Brain Ischemia | 9 | 2022 | 292 | 1.040 |
Why?
|
| Telemedicine | 5 | 2022 | 471 | 0.650 |
Why?
|
| Kentucky | 12 | 2024 | 20 | 0.510 |
Why?
|
| Ohio | 10 | 2024 | 113 | 0.410 |
Why?
|
| Fibrinolytic Agents | 5 | 2022 | 324 | 0.370 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2022 | 163 | 0.360 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2024 | 95 | 0.360 |
Why?
|
| Stroke Rehabilitation | 2 | 2020 | 61 | 0.350 |
Why?
|
| Emergency Medical Services | 4 | 2018 | 429 | 0.340 |
Why?
|
| Hyperglycemia | 2 | 2014 | 333 | 0.330 |
Why?
|
| Sex Factors | 7 | 2020 | 2139 | 0.310 |
Why?
|
| Veterans | 4 | 2023 | 1641 | 0.310 |
Why?
|
| Brain | 2 | 2012 | 4113 | 0.280 |
Why?
|
| Mushroom Bodies | 1 | 2005 | 48 | 0.260 |
Why?
|
| Intracranial Aneurysm | 2 | 2018 | 123 | 0.240 |
Why?
|
| Apolipoprotein E2 | 2 | 2014 | 13 | 0.240 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2023 | 16 | 0.230 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 142 | 0.220 |
Why?
|
| Opiate Alkaloids | 1 | 2022 | 6 | 0.220 |
Why?
|
| Emergency Service, Hospital | 6 | 2022 | 1148 | 0.210 |
Why?
|
| Axons | 1 | 2005 | 403 | 0.210 |
Why?
|
| Endocarditis | 1 | 2023 | 125 | 0.200 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 181 | 0.200 |
Why?
|
| Cocaine | 1 | 2022 | 233 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 849 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 55 | 0.170 |
Why?
|
| Hypertension | 2 | 2023 | 1503 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 164 | 0.170 |
Why?
|
| Thrombolytic Therapy | 3 | 2022 | 257 | 0.170 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 858 | 0.170 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 225 | 0.170 |
Why?
|
| Aged | 24 | 2023 | 70117 | 0.160 |
Why?
|
| Deprescriptions | 1 | 2017 | 24 | 0.160 |
Why?
|
| Certification | 1 | 2019 | 123 | 0.160 |
Why?
|
| Cerebral Arteries | 1 | 2018 | 73 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 524 | 0.150 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 87 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2019 | 636 | 0.150 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 276 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2019 | 291 | 0.150 |
Why?
|
| Platelet Transfusion | 1 | 2017 | 156 | 0.150 |
Why?
|
| Troponin | 1 | 2017 | 92 | 0.150 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 29902 | 0.140 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2017 | 110 | 0.140 |
Why?
|
| Cerebral Angiography | 1 | 2017 | 129 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2014 | 5539 | 0.140 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2017 | 105 | 0.140 |
Why?
|
| Urban Population | 1 | 2017 | 269 | 0.140 |
Why?
|
| Humans | 40 | 2024 | 261506 | 0.140 |
Why?
|
| Male | 27 | 2023 | 123000 | 0.140 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 12 | 0.140 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2015 | 10 | 0.140 |
Why?
|
| Epilepsy | 1 | 2024 | 883 | 0.140 |
Why?
|
| Cerebral Ventricles | 1 | 2016 | 98 | 0.130 |
Why?
|
| Case-Control Studies | 6 | 2016 | 6100 | 0.130 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 58 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 598 | 0.130 |
Why?
|
| Middle Aged | 21 | 2024 | 86204 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 252 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 915 | 0.130 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 149 | 0.130 |
Why?
|
| Risk Factors | 9 | 2023 | 17523 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 235 | 0.120 |
Why?
|
| Neurons | 1 | 2005 | 2287 | 0.120 |
Why?
|
| Prospective Studies | 8 | 2017 | 12873 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 719 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2018 | 747 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 3343 | 0.120 |
Why?
|
| Female | 25 | 2023 | 141928 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 444 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2018 | 1467 | 0.120 |
Why?
|
| Warfarin | 1 | 2014 | 152 | 0.110 |
Why?
|
| White Matter | 1 | 2015 | 195 | 0.110 |
Why?
|
| Genotype | 4 | 2014 | 4109 | 0.110 |
Why?
|
| SOXF Transcription Factors | 1 | 2012 | 34 | 0.110 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 221 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 327 | 0.110 |
Why?
|
| Incidence | 5 | 2024 | 5673 | 0.110 |
Why?
|
| Time Factors | 7 | 2022 | 12926 | 0.110 |
Why?
|
| Intracranial Hemorrhages | 1 | 2013 | 121 | 0.110 |
Why?
|
| Sleep | 1 | 2015 | 413 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 2015 | 431 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 228 | 0.100 |
Why?
|
| Echocardiography | 1 | 2017 | 1182 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2017 | 691 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2017 | 732 | 0.090 |
Why?
|
| Prevalence | 4 | 2022 | 3260 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 2403 | 0.090 |
Why?
|
| Contrast Media | 1 | 2017 | 1472 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 855 | 0.090 |
Why?
|
| Retrospective Studies | 10 | 2023 | 37905 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 739 | 0.090 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 2265 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 1479 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1362 | 0.070 |
Why?
|
| RNA, Long Noncoding | 1 | 2012 | 598 | 0.070 |
Why?
|
| Phenotype | 1 | 2018 | 6295 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 4053 | 0.070 |
Why?
|
| Treatment Outcome | 9 | 2017 | 32848 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 145 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2021 | 899 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4298 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2005 | 154 | 0.060 |
Why?
|
| Larva | 1 | 2005 | 274 | 0.060 |
Why?
|
| Age Factors | 3 | 2020 | 5377 | 0.060 |
Why?
|
| United States | 5 | 2023 | 15433 | 0.060 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2005 | 159 | 0.060 |
Why?
|
| Neurologists | 1 | 2024 | 19 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2195 | 0.060 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 406 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 694 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2005 | 306 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 1062 | 0.060 |
Why?
|
| Educational Status | 1 | 2024 | 397 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 445 | 0.050 |
Why?
|
| Adult | 6 | 2024 | 77950 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2023 | 9244 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 435 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 2316 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 40 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 306 | 0.050 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 67 | 0.050 |
Why?
|
| Occupational Health | 1 | 2021 | 95 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 4320 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 259 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 3441 | 0.050 |
Why?
|
| Emotions | 1 | 2024 | 562 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2005 | 1152 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 577 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 829 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1498 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 485 | 0.040 |
Why?
|
| Rats, Inbred BN | 1 | 2018 | 34 | 0.040 |
Why?
|
| Basilar Artery | 1 | 2018 | 25 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 495 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2018 | 101 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 603 | 0.040 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 11 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 215 | 0.040 |
Why?
|
| Rats | 2 | 2018 | 6086 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 14889 | 0.040 |
Why?
|
| Ligation | 1 | 2018 | 193 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 2927 | 0.040 |
Why?
|
| Ventriculostomy | 1 | 2017 | 34 | 0.040 |
Why?
|
| Halogenation | 1 | 2017 | 14 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 294 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 605 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 661 | 0.040 |
Why?
|
| Animals | 4 | 2018 | 59536 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2018 | 392 | 0.040 |
Why?
|
| Models, Biological | 1 | 2005 | 3254 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 787 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 249 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2021 | 674 | 0.030 |
Why?
|
| Rats, Inbred WKY | 1 | 2015 | 110 | 0.030 |
Why?
|
| Rats, Inbred SHR | 1 | 2015 | 113 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 649 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 343 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 292 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 1323 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2019 | 621 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 876 | 0.030 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2013 | 9 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 860 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 7222 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 827 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 1371 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 374 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 846 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 1533 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2005 | 5270 | 0.020 |
Why?
|
| Young Adult | 2 | 2022 | 21445 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 929 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1303 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2006 | 11965 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 4988 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 6150 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 2315 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 4314 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 2588 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 6682 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 15179 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9180 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 2440 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7551 | 0.010 |
Why?
|
| Child | 1 | 2022 | 29154 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 4549 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 21713 | 0.010 |
Why?
|